The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure

Cardiology (Switzerland)

Volumn 131, Issue 1, 2015, Pages 22-29

  Grajek, Stefan ^a   Michalak, Michał ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adjunctive treatment; Heart failure; Metabolic approach; Mortality; Trimetazidine

Indexed keywords

TRIMETAZIDINE; VASODILATOR AGENT;

ADD ON THERAPY; ARTICLE; CAUSE OF DEATH; DRUG EFFECT; ECHOCARDIOGRAPHY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC HEART FAILURE; HEART FAILURE, SYSTOLIC; MORTALITY;

HEART FAILURE, SYSTOLIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84926158491     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000375288     Document Type: Article

References (35)

1. Tang WH: The metabolic approach in patients with heart failure: effects on left ventricle remodelling. Curr Pharm Des 2009; 15: 850-856.
2. Fragasso G, Salerno A, Spoladore R, Bassanelli G, Arioli F, Margonato A: Metabolic therapy of heart failure. Curr Pharm Des 2008; 14: 2582-2591.
3. Neubauer S: The failing heart-an engine out of fuel. N Engl J Med 2007; 356: 1140-1151.
4. Weiss RG, Gerstenblith G, Bottomley PA: ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc Natl Acad Sci U S A 2005; 102: 808-813.
5. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85: 1093-1129.
6. Lionetti V, Stanley WC, Recchia FA: Modulating fatty acid oxidation in heart failure. Cardiovasc Res 2011; 90: 202-209.
7. Lopaschuk GD: Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin Cardiothorac Vasc Anesth 2006; 10: 228-230.
8. Di Napoli P, Barsotti A: Prognostic relevance of metabolic approach in patients with heart failure. Curr Pharm Des 2009; 15: 883-892.
9. Belardinelli R, Solenghi M, Volpe L, Purcaro A: Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007; 28: 1102-1108.
10. Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, et al: Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008; 118: 1250-1258.
11. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A: Effect of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-948.
12. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S: Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005; 5: 271-278.
13. Lavanchy N, Martin J, Rossi A: Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110.
14. Yabe T, Mitsunami K, Inubushi T, Kinoshita M: Quantitative measurements of cardiac phosphorus metabolites in coronary artery disease by 31P magnetic resonance spectroscopy. Circulation 1995; 92: 15-23.
15. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina A, Allen PD: The creatine kinase system in failing and nonfailing human myocardium. Circulation 1996; 94: 1894-1901.
16. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K: Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-2196.
17. Gao D, Ning N, Niu X, Hao G, Meng Z: Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart 2011; 97: 278-286.
18. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J: Additional use of trimetazidine in patients with chronic heart failure. J Am Coll Cardiol 2012; 59: 913-922.
19. Huang C, Dong B: Effects of trimetazidine for coronary heart failure: a systematic review. Chin J Evid Based Med 2007; 7: 37-44.
20. Fragasso G, Rosano G, Baek SH, et al: Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol 2013; 163: 320-325.
21. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-998.
22. Di Napoli P, Di Giovannini P, Gaeta M, Taccardi A, Barsotti A: Trimetazidine and reduction in mortality and hospitalization patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007; 50: 585-589.
23. Iyengar S, Rosano G: Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction. A preliminary study (METRO). Am J Cardiovasc Drugs 2009; 9: 293-297.
24. Higgins JPT, Green S; Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions. http://www.cochrane. org/training/cochrane-handbook.
25. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
26. Sterne JAC, Egger M, Smith GD: Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
27. Lopatin YM, et al: Abstract 2052. ESC Congress, Munich, 2012.
28. Ciapponi A, Pizarro R, Harrison J: Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4:CD003614.
29. Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP: Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011; 120: 59-72.
30. Marzilli M, Klein WW: Efficacy and tolerability of trimetazidine in stable angina: a metaanalysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003; 14: 171-179.
31. McClellan KJ, Plosker GL: Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999; 58: 143-157.
32. Szwed H, Sadowski Z, Elikowski W, et al: Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J 2001; 22: 2267-2274.
33. Di Napoli P, Taccardi A, Barsati A: Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart 2005; 91: 161-165.
34. Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M, Rosano GM: Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina-The VASCO-angina study. Int J Cardiol 2013; 168: 1078-1081.
35. Sellier P, Broustet JP: Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003; 3: 361-369.